Eagle Pharmaceuticals, Inc.
EGRX
EGRX was delisted on the 2nd of October, 2024.
170 hedge funds and large institutions have $853M invested in Eagle Pharmaceuticals, Inc. in 2017 Q4 according to their latest regulatory filings, with 28 funds opening new positions, 55 increasing their positions, 58 reducing their positions, and 25 closing their positions.
12% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 25
10% more call options, than puts
Call options by funds: $5.53M | Put options by funds: $5.04M
1% more funds holding
Funds holding: 169 → 170 (+1)
5% less repeat investments, than reductions
Existing positions increased: 55 | Existing positions reduced: 58
10% less capital invested
Capital invested by funds: $947M → $853M (-$94.6M)
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LSV Asset Management
Chicago,
Illinois
|
+$28.2M |
| 2 |
Prudential Financial
Newark,
New Jersey
|
+$10M |
| 3 |
PWAM
Park West Asset Management
San Francisco,
California
|
+$7.13M |
| 4 |
PP
PDT Partners
New York
|
+$5.89M |
| 5 |
IAM
Iridian Asset Management
Westport,
Connecticut
|
+$4.87M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$11.9M |
| 2 |
State Street
Boston,
Massachusetts
|
-$11.5M |
| 3 |
Janus Henderson Group
London,
United Kingdom
|
-$8.14M |
| 4 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$7.75M |
| 5 |
GAM
Gotham Asset Management
New York
|
-$6.95M |
EGRX Hedge Fund Activity: Q4 2017 in Review
170 of the 4,410 institutional investors tracked by Wall St. Rank reported a position in Eagle Pharmaceuticals, Inc. (EGRX) for Q4 2017, worth a combined $853M — down 10% from $947M a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new EGRX positions and 25 closed out — a net gain of 3 holders — while 55 added to existing stakes and 58 trimmed.
The largest buyer was LSV Asset Management, adding an estimated $28.2M. The largest seller was Cormorant Asset Management, exiting entirely with an estimated $11.9M sold.
- 170 institutional investors held Eagle Pharmaceuticals, Inc. (EGRX) as of Q4 2017, up from 169 in Q3 2017.
- Funds reported $853M of Eagle Pharmaceuticals, Inc. stock for Q4 2017, down 10% quarter-over-quarter.
- 28 funds opened new Eagle Pharmaceuticals, Inc. positions in Q4 2017 and 25 closed out, a net change of +3 holders.
- The largest Eagle Pharmaceuticals, Inc. buyer in Q4 2017 was LSV Asset Management, an estimated $28.2M added.
- The largest Eagle Pharmaceuticals, Inc. seller in Q4 2017 was Cormorant Asset Management, an estimated $11.9M sold.
Based on aggregated 13F filings for Q4 2017.